AnaptysBio, Inc. $ANAB Shares Sold by First Light Asset Management LLC

First Light Asset Management LLC reduced its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 12.5% during the 1st quarter, Holdings Channel reports. The fund owned 565,431 shares of the biotechnology company’s stock after selling 80,807 shares during the period. AnaptysBio makes up about 2.8% of First Light Asset Management LLC’s holdings, making the stock its 13th largest holding. First Light Asset Management LLC’s holdings in AnaptysBio were worth $31,359,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 821 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after buying an additional 263 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of AnaptysBio by 940.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 1,383 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in shares of AnaptysBio by 987.3% during the 4th quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company’s stock valued at $83,000 after buying an additional 1,560 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Zacks Research lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Barclays lifted their target price on shares of AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Piper Sandler reduced their price target on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. HC Wainwright began coverage on shares of AnaptysBio in a research note on Wednesday, June 10th. They issued a “buy” rating and a $95.00 price target on the stock. Finally, UBS Group boosted their price objective on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

AnaptysBio Price Performance

ANAB opened at $54.15 on Monday. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -50.14 and a beta of 0.68. The company’s 50 day simple moving average is $58.38 and its two-hundred day simple moving average is $57.57. AnaptysBio, Inc. has a 1-year low of $11.40 and a 1-year high of $72.36.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. On average, equities analysts anticipate that AnaptysBio, Inc. will post -1.35 earnings per share for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.